ADRB3 and melanoma: Recently, it has been demonstrated that in murine B16-F10 melanoma-bearing mice, the pharmacological β3-AR blockade was able to reduce the expression of cancer stem cell (CSC) markers, and to induce a differentiated phenotype of numerous hematopoietic progenitors recruited in TME [91].